CU6 clarity pharmaceuticals ltd

Great!"...This study showed that 64Cu-SAR-bisPSMA is effective...

  1. 1,108 Posts.
    lightbulb Created with Sketch. 1296
    Great!

    "...
    1. This study showed that 64Cu-SAR-bisPSMA is effective in detecting lesions in PC patients with BCR, who had a negative or equivocal SOC scan at study entry.
    2. More lesions and more participants with a positive scan were identified earlier by 64Cu-SAR-bisPSMA vs. SOC PSMA imaging.
    3. Results indicate that 64Cu-SAR-bisPSMA is able to identify lesions from 29 days to more than 6 months earlier than SOC PSMA agents.
    4. Lesions <5 mm in diameter were identified by 64Cu-SAR-bisPSMA in 14% of participants.

    These findings have important clinical implications as the early identification of lesions in BCR patients can inform different treatment pathways.
    ..."
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$4.11
Change
-0.200(4.64%)
Mkt cap ! $1.329B
Open High Low Value Volume
$4.20 $4.27 $4.09 $7.447M 1.792M

Buyers (Bids)

No. Vol. Price($)
1 1000 $4.11
 

Sellers (Offers)

Price($) Vol. No.
$4.12 2000 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.